These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23970394)

  • 1. When EMA and FDA decisions conflict: differences in patients or in regulation?
    Wolfe SM
    BMJ; 2013 Aug; 347():f5140. PubMed ID: 23970394
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 4. Preparing for an FDA preapproval inspection.
    Blackmer RA
    Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 6. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 7. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.
    Trotta F; Leufkens HG; Schellens JH; Laing R; Tafuri G
    J Clin Oncol; 2011 Jun; 29(16):2266-72. PubMed ID: 21537038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of FDA and EMA drug approval: implications for drug development and cost of care.
    Howie LJ; Hirsch BR; Abernethy AP
    Oncology (Williston Park); 2013 Dec; 27(12):1195, 1198-1200, 1202 passim. PubMed ID: 24624536
    [No Abstract]   [Full Text] [Related]  

  • 12. Muddied messages about FDA.
    Miller HI
    Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
    [No Abstract]   [Full Text] [Related]  

  • 13. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 14. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA performance goals for approving drugs and biologics.
    Miller JD
    JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
    [No Abstract]   [Full Text] [Related]  

  • 16. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 19. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
    Mogielnicki M; Swieczkowski D; Bachorski W; Zuk G; Gilis-Malinowska N; Zarzeka A; Merks P; Gruchala M; Jaguszewski M
    Cardiol J; 2016; 23(5):515-517. PubMed ID: 27723064
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.